{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:52:07Z","timestamp":1792572727041,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.diagmicrobio.2026.117298","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:39:52Z","timestamp":1769701192000},"page":"117298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United States"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-6855","authenticated-orcid":false,"given":"Joshua M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117298_bib0001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/sur.2020.436","article-title":"Surgical infection society 2020 updated guidelines on the management of complicated skin and soft tissue infections","volume":"22","author":"Duane","year":"2021","journal-title":"Surg Infect"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117298_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ph13110333","article-title":"New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics","volume":"13","author":"Principi","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.diagmicrobio.2026.117298_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","article-title":"Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010","volume":"15","author":"Miller","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117298_bib0004","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/cid\/ciy509","article-title":"Decreasing incidence of skin and soft-tissue infections in 86 US emergency departments, 2009-2014","volume":"68","author":"Morgan","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117298_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","article-title":"Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus","volume":"51","author":"Pallin","year":"2008","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117298_bib0006","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.diagmicrobio.2026.117298_bib0007","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117298_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14787210.2021.1927711","article-title":"Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Lan","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117298_bib0009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117298_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2026.117298_bib0011","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with Vancomycin plus Aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117298_bib0012","unstructured":"FDA. ZEVTERA (ceftobiprole medocaril sodium for injection), for intravenous use. 2024."},{"key":"10.1016\/j.diagmicrobio.2026.117298_bib0013","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2024","journal-title":"Regist Name Updat"},{"key":"10.1016\/j.diagmicrobio.2026.117298_bib0014","article-title":"Performance Standards for antimicrobial susceptability testing; 35the informational supplement","year":"2025","journal-title":"Regist Name Updat"},{"key":"10.1016\/j.diagmicrobio.2026.117298_bib0015","series-title":"Antibacterial Susceptibility Test Interpretive Criteria","year":"2025"},{"key":"10.1016\/j.diagmicrobio.2026.117298_bib0016","volume":"2025","year":"2025"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117298_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.116838","article-title":"In Vitro activity of ceftobiprole against 20,255 recent clinical bacterial isolates in Canada (CANWARD 2015-2023)","volume":"112","author":"Gemme","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 3)","key":"10.1016\/j.diagmicrobio.2026.117298_bib0018","first-page":"3","article-title":"Mechanisms of action and antimicrobial activity of ceftobiprole","author":"Morosini","year":"2019","journal-title":"Rev Esp Quim"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326000489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326000489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:18:11Z","timestamp":1774001891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889326000489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0732889326000489"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117298","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United States","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117298"}}